secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001654954-23-003383
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar FY2022 net loss $10.5M; Validive interim readout due next week; camsirubicin dose-escalation continues
--------------------------------------------------------------------------------

- Net loss FY2022 $10.5M ($0.83/share) vs $9.1M ($0.73/share) in 2021; cash $13.1M.
- Validive Phase 2b/3 VOICE trial interim analysis go/no-go readout expected by end of next week.
- Camsirubicin Phase 1b enrolling 5th dose level (650 mg/m²); no cardiotoxicity, 75% no hair loss.
- CFO Kim Tsuchimoto appointed to board; board size increased to six.
- Current funds expected to cover camsirubicin topline results by end 2023; additional funding sought within 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/0001654954-23-003383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000165495423003383/mnpr_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-003383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer